<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683941</url>
  </required_header>
  <id_info>
    <org_study_id>A-US-52030-328</org_study_id>
    <secondary_id>2015-004992-62</secondary_id>
    <nct_id>NCT02683941</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors</brief_title>
  <acronym>SPINET</acronym>
  <official_title>A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumor Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, prospective, multi-center, randomized, double-blind, study evaluating the
      efficacy and safety of LAN plus BSC versus placebo plus BSC for the treatment of
      well-differentiated, metastatic and/or unresectable, typical or atypical lung NETs.

      This study contains two phases: the Double-Blind (DB) Phase, and the Open Label (OL)
      Extension Phase. The DB Phase includes: Screening, Baseline and Treatment period. The OL
      Extension Phase will consist of two periods: Treatment Period and Follow-Up Period.

      The primary objective will be to compare the antitumour efficacy of Lanreotide Autogel/Depot
      120 mg (LAN) plus Best Supportive Care (BSC) every 28 days versus placebo plus BSC, in terms
      of progression-free survival (PFS), measured by central review using Response Evaluation
      Criteria in Solid Tumours (RECIST) v1.1 criteria, every 12 weeks, in subjects with
      unresectable and/or metastatic well differentiated, typical or atypical lung neuroendocrine
      tumours.

      Recent updates of NCCN &amp; ENETS guidelines recommend SSA in first line for the treatment of
      locoregional unresectable or metastatic lung NETs as an option beyond
      'observation''observation' leading to slow and difficult recruitment in SPINET study.
      Consequently, it was decided to prematurely stop the recruitment in the SPINET study and to
      transition all subjects still treated in the double-blind phase to the open label (OL)
      Extention following respective country approvals of Amendment #5.

      The new aim of this Phase 3, multicenter, prospective, randomized placebo-controlled clinical
      study is to describe the antitumor efficacy and safety of Lanreotide Autogel/Depot 120 mg
      (LAN) plus Best Supportive Care (BSC) in subjects with well-differentiated, metastatic and/or
      unresectable, typical or atypical, lung NETs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As planned initially, a total of 216 eligible patients with well-differentiated typical or
      atypical, metastatic and/or unresectable lung NETs, and a positive somatostatin receptor
      imaging (SRI) (Octreoscan® ≥ grade 2 Krenning scale; Ga-PET scan: uptake greater than liver
      background), had to be randomized 2:1 to either LAN plus BSC (120mg/28 days) or placebo plus
      BSC following the stratification of 1) typical versus atypical and 2) prior chemotherapy
      versus no prior chemotherapy*. At the time of the premature stop of the recruitment (as per
      Protocol Amendment #5), 77 patients have been enrolled. All patients still treated in the DB
      Phase have been entered into the OL Extention Phase (either for Follow up or for OL treatment
      periods). The transition to the OL Extention periods was done on a country-basis and per
      patient, at the following planned scheduled visit (i.e. approximately 28 days from the last
      injection). Patients enrolled into the study not progressing at the time of transition, and
      who agree to stay on LAN therapy (i.e. OL Treatment Period) not progressing at the time of
      transition, and who agree to stay on LAN therapy (i.e. OL Treatment Period) will receive the
      study active treatment until evidence of disease progression (based on local radiological
      assessment then confirmed centrally), development of unacceptable toxicity, or premature
      withdrawal for any reason or up a maximum of 18 months after the last patient randomized.
      After disease progression patients are followed for survival, QoL and all subsequent
      anticancer treatments in the OL Follow-up period up to the end of the study (i.e up to 18
      months after the last patient randomized).

      * cytotoxic chemotherapy or molecular targeted therapy or interferon.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS), for subjects randomized in LAN group, assessed by central review using RECIST v1.1 criteria</measure>
    <time_frame>From randomization up to disease progression or up to 18 months (approximately) after the last patient is randomized either in the DB period or in the OL period. .</time_frame>
    <description>PFS measured by central review using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria, every 12 weeks, defined as the time from randomization to disease progression or death from any causes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS), assessed by central review using RECIST v1.1 criteria every 12 weeks,</measure>
    <time_frame>From randomization to disease progression or death from any causes during the double-blind phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS), assessed by local review using RECIST v1.1 criteria every 12 weeks</measure>
    <time_frame>From randomization to disease progression or death from any causes during the double-blind phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR: objective response rate measured by RECIST v1.1 criteria every 12 weeks</measure>
    <time_frame>From randomisation up to the Post Treatment/Early Withdrawal Visit during the double-blind phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure during the double-blind phase</measure>
    <time_frame>From randomisation up to event according to central review or to event according to local review whatever the one which occurs first</time_frame>
    <description>Defined as the time from randomization to disease progression using RECIST v1.1, death, consent withdrawn, an AE, protocol deviations, lost to follow-up, the appearance of carcinoid syndrome or other hormone related syndrome necessitating the initiation of SSAs (rescue octreotide and/or LAR SSA), or initiation of anticancer treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes from Baseline in the biomarker chromogranin A (CgA)</measure>
    <time_frame>Every 12 weeks thereafter until the post Double-Blind and in the Open Label Extension Treatment Phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a decrease of CgA ≥30% at week 8 in the population of subjects with an elevated CgA (≥2 x ULN) at Baseline</measure>
    <time_frame>Double-blind and the Open-label treatment phases</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QoL), as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30</measure>
    <time_frame>Baseline, week 12, every 12 weeks and at the Post treatment/Early Withdrawal Visit and in the OL Extension Treatment and Follow-up phases</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to QoL deterioration, defined by a decrease from baseline in EORTC Quality of Life Questionnaire C30 (QLQ-C30) score of at least 10 points</measure>
    <time_frame>Double-blind, Open-label Treatment and Follow-up phases</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes from Baseline in urinary 5-HIAA levels in subjects with elevated urinary 5-hydroxyindoleacetic acid (5-HIAA) (≥2 x Upper limit of normal range) at Baseline</measure>
    <time_frame>Every 12 weeks thereafter, and at the Post Treatment/Early Withdrawal Visit and in the Open-label Extension Treatment phase</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Neuroendocrine Tumors in Lung</condition>
  <arm_group>
    <arm_group_label>Lanreotide (Autogel formulation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120mg every 28 days until disease progression, death, or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>120mg every 28 days until disease progression, death, or unacceptable toxicity then patient may enter open-label treatment with Lanreotide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide (Autogel formulation)</intervention_name>
    <description>120mg every 28 days until disease progression, death, or unacceptable toxicity</description>
    <arm_group_label>Lanreotide (Autogel formulation)</arm_group_label>
    <other_name>Lanreotide Depot (US)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have metastatic and/or unresectable pathologically confirmed well-differentiated,
             typical or atypical neuroendocrine tumor of the lung

          -  Histologic evidence of Well differentiated Neuroendocrine tumors (NETs) of the lung
             (typical and atypical according to the World Health Organisation (WHO criteria),
             evaluated locally)

          -  Has a mitotic index &lt;2 mitoses/2 mm2 for typical carcinoid (TC) and &lt;10 mitoses/2 mm2
             and/or foci of necrosis for atypical carcinoid (AC)

          -  At least one measurable lesion of the disease on imaging (CT or MRI; RECIST 1.1)

          -  Positive Somatostatin receptors (SSTR) imaging

        Exclusion Criteria:

          -  Poorly differentiated or high grade carcinoma, or patients with neuroendocrine tumors
             not of lung origin

          -  Has been treated with a Somatostatin analog (SSA) at any time prior to randomization,
             except if that treatment was for less than 15 days (e.g. peri-operatively) of short
             acting SSA or one dose of long acting SSA and the treatment was received more than 6
             weeks prior to randomization

          -  Has been treated with Peptide receptor radionuclide therapy (PRRT) at any time prior
             to randomization

          -  Has been treated with more than two lines of cytotoxic chemotherapy or molecular
             targeted therapy or interferon for Lung NET
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Greater Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Forth Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH und Med. University Vienna Allg Krankenhaus Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>2TN 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3E0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NET-Centre, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLLC, Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier (ICM) Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau ICO institut de Cancerologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Lungenklinik Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen (AöR)</name>
      <address>
        <city>Essen</city>
        <zip>45145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe-Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Genova</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insituti Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Antonio Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Perugia Santa Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <zip>06123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insittuto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zakladu Medycyny Nuklearne i Endokrynologii Onkologicznej</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Center of Ophtalmology &amp; Oncology</name>
      <address>
        <city>Katowice</city>
        <zip>40-514</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki W</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. H. Święcickiego U.M.</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GAMMED</name>
      <address>
        <city>Warszawa</city>
        <zip>02-348</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari, Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28412</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center, Beatson Oncology</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QC</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>February 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

